A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

  • Vormoor et al.
  • B. Vormoor, G. J. Veal, M. J. Griffin, A. V. Boddy, J. Irving, L. Minto, M. Case, U. Banerji, K. E. Swales, J. R. Tall, A. S. Moore, M. Toguchi, G. Acton, K. Dyer, C. Schwab, C. J. Harrison, J. D. Grainger, D. Lancaster, P. Kearns, D. Hargrave, J. Vormoor
  • Pediatric Blood & Cancer, December 2016, Wiley
  • DOI: 10.1002/pbc.26351

The authors haven't yet claimed this publication.

Read Publication


In partnership with: